Investors are betting big on Regeneron: Its market value has jumped by more than a fifth in 2017. Why? Sales of eye-disease treatment Eylea are strong. The company’s expansive pipeline could continue to fuel steady growth. Regeneron has 11 experimental treatments in Phase II or Phase III clinical trials. One that could prove critical is REGN2810, a type of next-generation medicine currently in late-stage studies that harnesses the body’s immune system to fight cancer.
Looking for leads, investment insights, or competitive intelligence?
News about Regeneron Pharmaceuticals
Scientists are ready to move an experimental treatment into phase 1 trials.
“We should only be working on two things, health and the freaking environment.”
But Dupixent's high cost could be a problem.
They say a robust review process is needed to convince doctors and insurers new drugs have value.
It's to protect the company's best-selling drug.